IPO Year: 2025
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/31/2025 | $30.00 | Buy | BofA Securities |
3/31/2025 | $29.00 | Outperform | Wolfe Research |
3/31/2025 | $24.00 | Neutral | Goldman |
3/31/2025 | $28.00 | Buy | Stifel |
3/31/2025 | $28.00 | Overweight | Wells Fargo |
3/31/2025 | $27.00 | Overweight | Piper Sandler |
KIRKLAND, Wash., April 30, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, is scheduled to participate in the following upcoming investor conferences: Event: BofA Securities 2025 Health Care ConferenceDate: Wednesday, May 14Presentation time: 6:40 p.m. ET Event: Goldman Sachs 46th Annual Global Healthcare Conference 2025Date: Wednesday, June 11Presentation time: 8:00 a.m. ET Interested parties may access a live webcast and replay of each presentation by visiting the Kestra Medical Technologies investor relations website. About KestraKestra Medical Technologies, Ltd. is a commercial-stage
KIRKLAND, Wash., April 29, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) ("Kestra"), a wearable medical device and digital healthcare company, today announced the presentation of new real-world data on the ASSURE® Wearable Cardioverter Defibrillator (WCD) at Heart Rhythm 2025, the annual meeting of the Heart Rhythm Society (HRS), held April 24–27 in San Diego. The abstract, titled "Real-world Experience with a Novel Wearable Cardioverter Defibrillator in a Community Setting: Advanced Practice Provider-Driven Care Model," was developed in partnership with Ashley L. Dailey, ANP-BC, MSN and Opesanmi O. Esan, MD, and presented at the annual meeting. The abstract e
KIRKLAND, Wash., April 23, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) ("Kestra"), a wearable medical device and digital healthcare company, announced today it will exhibit at Heart Rhythm 2025, the annual meeting of the Heart Rhythm Society (HRS), taking place April 24-27 at the San Diego Convention Center. This marks Kestra's first major industry showcase following its successful IPO earlier this year. Kestra will debut an immersive in-booth experience designed to bring the ASSURE® system to life—demonstrating how this innovative technology is redefining protection for patients at risk of sudden cardiac arrest. By combining lifesaving defibrillation therap
KIRKLAND, Wash., April 14, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) ("Kestra"), a wearable medical device and digital healthcare company, today reported financial results for the third quarter fiscal 2025, which ended January 31, 2025. Recent Highlights Q3 FY25 revenue and gross margin were in line with the preliminary estimated financial results previously disclosed in the company's IPO prospectus. Generated revenue of $15.1 million in Q3 FY25, an increase of 82% compared to the prior year period.Achieved gross margin of 43.4% in Q3 FY25 compared to 10.6% in the prior year period. Completed initial public offering in March 2025, raising approximatel
Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son
KIRKLAND, Wash., April 02, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that it will report financial results for the third quarter fiscal 2025 on Monday, April 14. Management will host a corresponding conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable
10-Q - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)
8-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)
Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son
BofA Securities initiated coverage of Kestra Medical Technologies with a rating of Buy and set a new price target of $30.00
Wolfe Research initiated coverage of Kestra Medical Technologies with a rating of Outperform and set a new price target of $29.00
Goldman initiated coverage of Kestra Medical Technologies with a rating of Neutral and set a new price target of $24.00
Stifel initiated coverage of Kestra Medical Technologies with a rating of Buy and set a new price target of $28.00
Wells Fargo initiated coverage of Kestra Medical Technologies with a rating of Overweight and set a new price target of $28.00
Piper Sandler initiated coverage of Kestra Medical Technologies with a rating of Overweight and set a new price target of $27.00
KIRKLAND, Wash., April 02, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that it will report financial results for the third quarter fiscal 2025 on Monday, April 14. Management will host a corresponding conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable